Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
611 hedge funds and large institutions have $29.1B invested in Alexion Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 86 funds opening new positions, 263 increasing their positions, 191 reducing their positions, and 75 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 8 → 12 (+4)
42% more capital invested
Capital invested by funds: $20.4B → $29.1B (+$8.62B)
38% more repeat investments, than reductions
Existing positions increased: 263 | Existing positions reduced: 191
15% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 75
0% more funds holding
Funds holding: 608 → 611 (+3)
11% less call options, than puts
Call options by funds: $196M | Put options by funds: $221M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$364M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$341M |
| 3 |
Jennison Associates
New York
|
+$188M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$174M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$130M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$437M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
-$269M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$139M |
| 4 |
D.E. Shaw & Co
New York
|
-$86.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$75M |
ALXN Hedge Fund Activity: Q1 2019 in Review
611 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2019, worth a combined $29.1B — up 42% from $20.4B a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new ALXN positions and 75 closed out — a net gain of 11 holders — while 263 added to existing stakes and 191 trimmed.
The largest buyer was Artisan Partners, adding an estimated $364M. The largest seller was T. Rowe Price Associates, cutting an estimated $437M.
- 611 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2019, up from 608 in Q4 2018.
- Funds reported $29.1B of Alexion Pharmaceuticals stock for Q1 2019, up 42% quarter-over-quarter.
- 86 funds opened new Alexion Pharmaceuticals positions in Q1 2019 and 75 closed out, a net change of +11 holders.
- The largest Alexion Pharmaceuticals buyer in Q1 2019 was Artisan Partners, an estimated $364M added.
- The largest Alexion Pharmaceuticals seller in Q1 2019 was T. Rowe Price Associates, an estimated $437M sold.
Based on aggregated 13F filings for Q1 2019.